Citigroup
COCP icon

Citigroup’s Cocrystal Pharma COCP Stock Holding History

Citigroup’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$1 – 5799
2026
Q1 		$1 Sell
1
-389
-100% -$401 ﹤0.01% 5853
2025
Q4 		$382 Sell
390
-663
-63% -$702 ﹤0.01% 5607
2025
Q3 		$1.32K Buy
+1,053
New +$1.63K ﹤0.01% 5584
2025
Q1 		– Sell
-3
Closed -$6 – 5653
2024
Q4 		$6 Buy
+3
New +$6 ﹤0.01% 5780
2019
Q2 		– Sell
-165
Closed -$5K – 7748
2019
Q1 		$5K Hold
165
– – ﹤0.01% 7414
2018
Q4 		$7K Sell
165
-125
-43% -$4.12K ﹤0.01% 7262
2018
Q3 		$9K Buy
290
+83
+40% +$3.71K ﹤0.01% 7376
2018
Q2 		$9K Buy
207
+83
+67% +$3.08K ﹤0.01% 7215
2018
Q1 		$9K Buy
+124
New +$7.74K ﹤0.01% 7074

Other funds holding COCP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's COCP Position: Q2 2026 in Review

Citigroup sold out of Cocrystal Pharma (COCP) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in COCP in Q1 2018 and held it in 9 quarters. The position peaked at $9K in Q3 2018. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • Citigroup reported no remaining Cocrystal Pharma position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Cocrystal Pharma share in Q2 2026, an estimated $1.
  • Citigroup first reported a position in Cocrystal Pharma in Q1 2018 and held it in 9 quarters.
  • Citigroup's Cocrystal Pharma position peaked at $9K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.